	Disparities in prostate cancer screening practices among general practitioners and urologists (PROSHADE study): A cross-sectional study. PLoS One Lumbreras B, Parker LA, Alonso-Coello P, Caballero-Romeu JP, Párraga-Martínez I, Prieto L, Moral-Peláez I, Del Campo-Giménez M, Gómez-Pérez L, Cebrián A, López-Garrigós M, Ronda E, Guilabert M, Canelo-Aybar C, Hernández-Aguado I. PMID: 42166422 [PubMed - indexed for MEDLINE]
	Tubulocystic Renal Cell Carcinoma: A Scoping Review of Radiological, Clinicopathological, and Immunohistochemical Features. Urol Int AbuHaweeleh MN, Alhyari A, Abuhayeh N, Emam F, Al-Qudimat AR, Al Rumaihi K, Khalil IA. PMID: 42166387 [PubMed - as supplied by publisher]
	Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma. JAMA Netw Open Shah NJ, Ababio Y, Eccleston A, Rao D, Kelly SP, Chang J, Lucht S, Paydar C, Van Doren BA, Bland E, John W, Giegerich S, Laney J, Feinberg B, Zarrabi KK. PMID: 42166160 [PubMed - indexed for MEDLINE]
	Androgen Receptor Expression in Urothelial Bladder Cancer-A Systematic Review and Meta-Analysis. ANZ J Surg Buckby A, Gholami M, Hong M, O'Callaghan M. PMID: 42165524 [PubMed - as supplied by publisher]
	Treatment and progression of patients in Sweden with metastatic castration-sensitive prostate cancer. Acta Oncol Styrke J, Jellvert Å, Hjälm Eriksson M, Sandin F, Axén E, Jabbar S, Juhl Norgaard K. PMID: 42165189 [PubMed - indexed for MEDLINE]
	Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical Surgery. Eur Urol Open Sci Tazawa S, Shinohara M, Kawashima Y, Sekine Y, Narita S, Kobayashi S, Abe N, Narita T, Fujita N, Mikami J, Okamoto T, Yamamoto H, Numakura K, Sato S, Habuchi T, Ohyama C, Hatakeyama S. PMID: 42164551 [PubMed]
	The role of CD36 in renal and bladder cancer. Discoveries (Craiova) Pavalean MI, Madan VL, Pavalean MC, Ceafalan LC, Hinescu ME. PMID: 42164471 [PubMed]
	Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer. Oncol Lett Liu X, Bao Y. PMID: 42164465 [PubMed]
	Bioinformatics analysis and experimental approach identify BRD-family gene DSP as a diagnostic and prognostic indicator in bladder cancer. Transl Androl Urol Liu Z, Tan T, Li S, Wang Y. PMID: 42164400 [PubMed]
	Advancing bladder cancer detection: commentary on a urinary DNA methylation diagnostic assay. Transl Androl Urol Duquesne I, Chakra MA, Myers AA, Boormans JL, Hayne D, Brown JA, O'Donnell MA. PMID: 42164398 [PubMed]
	Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study. Transl Androl Urol Xia Y, Ma B, Huang T, Liu X. PMID: 42164394 [PubMed]
	Single-port robotic surgery for kidney and upper tract cancer: a narrative review. Transl Androl Urol Daher K, Soputro NA, Younis SK, Al-Bayati A, Bernardino R, Watfa M, Rai S, Wang L, Ghandour R, Kaouk J, Autorino R. PMID: 42164392 [PubMed]
	Machine learning-based integration identifies lactylation biomarkers for prognosis prediction and tumor microenvironment modulation in bladder cancer. Transl Androl Urol Zhou X, Weng L, Sun T, Jiang Q, Zeng F, Xu C, Chang C, Wang Y, Zhou J. PMID: 42164391 [PubMed]
	Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis. Transl Androl Urol Dai Q, Tan X, Huang P, Zhang J, Zhu H. PMID: 42164378 [PubMed]
	Prostate imaging reporting and data system version 2.1 as a predictor of clinically significant and aggressive prostate cancer: a radical prostatectomy-validated study. Transl Androl Urol Pisuchpen N, Eurboonyanun K, O'Shea A, Lahoud RM, Atre ID, Harisinghani M. PMID: 42164375 [PubMed]
	Distant metastasis prediction in renal carcinoma: a retrospective cohort study using interpretable machine learning. Transl Androl Urol Wang Y, Chen Y, Zhou Z, Ding Y, Yuan J. PMID: 42164374 [PubMed]
	Identification and diagnostic model construction of cuproptosis-related biomarkers in bone metastatic prostate cancer. Transl Androl Urol Li J, Yao S, Luo J, Li T, Zhang J. PMID: 42164373 [PubMed]
	Bibliometric study on hotspots and trends of immunotherapy for kidney cancer from 2014 to 2024. Transl Androl Urol Guo Q, Nie Z. PMID: 42164368 [PubMed]
	Prostate cancer screening and evidence: the role of overall survival. Transl Androl Urol Takahashi T. PMID: 42164360 [PubMed]
	Urinary PENK DNA methylation for bladder cancer diagnosis: methodological rigor, interpretive boundaries, and the evidence required for clinical translation. Transl Androl Urol Delrue C, Oyaert M, Speeckaert MM. PMID: 42164358 [PubMed]

Articles 1 - 20 / 178407

Page 1 of 8921



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy